French drugmaker Sanofi anticipates to produce approximately 600 million doses of its coronavirus vaccine next year if its medical trials with GSK go as prepared, CEO Paul Hudson said Friday.
” Our company believe we are among the few companies who will be able to make a vaccine at a substantial scale,” he stated during an interview with CNBC’s “Squawk Box.”
Sanofi and GSK revealed Tuesday that they went into a contract to jointly produce a Covid-19 vaccine by the end of next year. The companies prepare to start clinical trials in the 2nd half of 2020 and, if effective, make it readily available to the public by the second half of 2021.
Sanofi and GSK are among a number of business working on a possible vaccine to avoid Covid-19, which has actually sickened more than 2.1 million individuals around the world and has eliminated at least 146,201 as of Friday morning, according to information put together by Johns Hopkins University.
There are currently no treatments to treat Covid-19 and drugmakers are racing to produce a vaccine, which is expected to take 12 to 18 months.
Moderna, in collaboration with the National Institutes of Health, a firm within the Department of Health and Human being Providers, started the very first human trial testing for a potential vaccine to avoid Covid-19 in March.
Johnson & Johnson stated it is aiming to produce between 600 million and 900 million doses of its potential coronavirus vaccine by the end of the first quarter of 2021 if human trials scheduled to start in September go as prepared.
Hudson stated Friday getting the U.S. and other parts of the world “back to normal” will require a vaccine.
In the meantime, Sanofi is donating doses of hydroxychloroquine, a malaria drug promoted by President Donald Trump as a prospective treatment. The drug is in scientific trials examining its efficiency in dealing with the coronavirus, however it is not a proven treatment.
